Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).

被引：0
|
作者：
Park, Keunchil
Lee, Jong-Seok
Lee, Ki Hyeong
Kim, Joo-Hang
Min, Young Joo
Cho, Jae Yong
Han, Ji-Youn
Kim, Bong-Seog
Kim, Jin-Soo
Lee, Dae Ho
Kang, Jin Hyoung
Cho, Eun Kyung
Jang, In-Jin
Jung, Jina
Kim, Hyo-Yeon
Sin, Hui Jung
Son, Jeewoong
Woo, Jong Soo
Kim, Dong-Wan
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol & Oncol, Seoul, South Korea
[2] Seoul Natl Univ, Dept Internal Med, Coll Med, Seoul Natl Unvers,Bundang Hosp, Soengnam, South Korea
[3] Chungbuk Natl Univ Hosp, Cheongju, South Korea
[4] Yonsei Canc Ctr, Seoul, South Korea
[5] Ulsan Univ Hosp, Dept Med, Ulsan, South Korea
[6] Gangnam Severance Hosp, Seoul, South Korea
[7] Natl Canc Ctr, Goyang, South Korea
[8] VHS Med Ctr, Seoul, South Korea
[9] Seoul Natl Univ, Dept Internal Med, Boramae Med Ctr, Seoul, South Korea
[10] Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea
[11] Seoul St Marys Hosp, Seoul, South Korea
[12] Gachon Univ, Gil Med Ctr, Dept Internal Med, Div Hematol & Oncol, Inchon, South Korea
[13] Seoul Natl Univ Hosp, Dept Clin Pharmacol, Seoul 110744, South Korea
[14] Hanmi Pharmaceut Co Ltd, Seoul, South Korea
[15] Seoul Natl Univ Hosp, Seoul 110744, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8084
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Spatiotemporal T790M heterogeneity in individual patients with non-small cell lung cancer (NSCLC) after acquired resistance to EGFR-tyrosine kinase inhibitor (TKI)
    Hata, Akito
    Katakami, Nobuyuki
    Yoshioka, Hiroshige
    Masago, Katsuhiro
    Fujita, Shiro
    Imai, Yukihiro
    Tomii, Keisuke
    Nishiyama, Akihiro
    Ishida, Tadashi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
    Masuda, Takeshi
    Miura, Satoru
    Sato, Yuki
    Tachihara, Motoko
    Bessho, Akihiro
    Nakamura, Atsushi
    Miyawaki, Taichi
    Yoshimine, Kohei
    Mori, Masahide
    Shiraishi, Hideaki
    Hamai, Kosuke
    Haratani, Koji
    Maeda, Sumiko
    Tabata, Eriko
    Kitagawa, Chiyoe
    Tanizaki, Junko
    Imai, Takumi
    Nogami, Shohei
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    Hattori, Noboru
    SCIENTIFIC REPORTS, 2023, 13 (01)
  • [23] Radiation to primary lesions in Patients with non-Oligometastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Mutation who do not Progress after TKI, Results of a Phase II Study
    Wang, Q.
    Li, J.
    Yao, W.
    Wu, L.
    Li, T.
    Lang, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E156 - E156
  • [24] Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
    Takeshi Masuda
    Satoru Miura
    Yuki Sato
    Motoko Tachihara
    Akihiro Bessho
    Atsushi Nakamura
    Taichi Miyawaki
    Kohei Yoshimine
    Masahide Mori
    Hideaki Shiraishi
    Kosuke Hamai
    Koji Haratani
    Sumiko Maeda
    Eriko Tabata
    Chiyoe Kitagawa
    Junko Tanizaki
    Takumi Imai
    Shohei Nogami
    Nobuyuki Yamamoto
    Kazuhiko Nakagawa
    Noboru Hattori
    Scientific Reports, 13
  • [25] Clinical Responses to EGFR-tyrosine Kinase Inhibitor Retreatment in Non-small Cell Lung Cancer Patients Who Benefited Prior Gefitinib Therapy
    Watanabe, S.
    Saida, Y.
    Ichikawa, K.
    Koshio, J.
    Baba, J.
    Miura, S.
    Tanaka, J.
    Kagamu, H.
    Narita, I.
    Yoshizawa, H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S618 - S619
  • [26] Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Janne, P. A.
    Son, J.
    Voccia, I.
    Uttenreuther-Fischer, M.
    Park, K.
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 145
  • [27] Phase II study of BI1482694 in patients (pts) with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI)
    Sun, J.
    Wang, Y. -M.
    Duan, Y. -Z.
    ANNALS OF ONCOLOGY, 2015, 26 : 145 - 145
  • [28] A phase II theranostic study with osimertinib in patients with EGFR-mutated non-small cell lung cancer (NSCLC) progressing on EGFR tyrosine kinase inhibitors (TKI) and undetectable EGFR T790M (THEROS)
    Wiesweg, M.
    Hense, J.
    Darwiche, K.
    Michels, S.
    Hautzel, H.
    Kobe, C.
    Metzenmacher, M.
    Herold, T.
    Zaun, G.
    Laue, K.
    Drzezga, A.
    Schildhaus, H-U.
    Wolf, J.
    Herrmann, K.
    Schuler, M. H. H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1084 - S1084
  • [29] Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors
    Taniguchi, Yoshihiko
    Tamiya, Akihiro
    Nakahama, Kenji
    Naoki, Yoko
    Kanazu, Masaki
    Omachi, Naoki
    Okishio, Kyoichi
    Kasai, Takahiko
    Atagi, Shinji
    ONCOLOGY LETTERS, 2017, 14 (06) : 7589 - 7596
  • [30] ERBB3 EXPRESSION ASSESSED BY IMMUNOHISTOCHEMISTRY (IHC) IN NON-SMALL CELL LUNG CANCER (NSCLC) TUMORS WITH EGFR MUTATION, BEFORE EGFR-TYROSINE-KINASE INHIBITOR (EGFR-TKI) EXPOSURE
    Felip, Enriqueta
    Hernandez-Losa, Javier
    Murtra-Garrell, Nuria
    Freixinos, Victor
    Salcedo, Maite
    Tallada, Natalia
    Teixido, Cristina
    Martinez, Pablo
    Cedres, Susana
    Lopez, Eva
    Pandielle, Anastasio
    Cajal, Santiago Ramon Y.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1104 - S1105
12345